1
|
Zhang Z, Tai Y, Liu Z, Pu Y, An L, Li X, Li L, Wang Y, Yang Z, Duan C, Hou K, Zhang Q, Ren F, Ma Q, Su Y. Effects of d-ribose on human erythrocytes: Non-enzymatic glycation of hemoglobin, eryptosis, oxidative stress and energy metabolism. Blood Cells Mol Dis 2023; 99:102725. [PMID: 36682143 DOI: 10.1016/j.bcmd.2023.102725] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2022] [Revised: 01/10/2023] [Accepted: 01/10/2023] [Indexed: 01/15/2023]
Abstract
d-Ribose is not only an important component of some biomacromolecules, but also an active pentose with strong reducibility and non-enzymatic glycation ability. Previous studies reported the diverse role of d-ribose in different cells. In this study, the effects of d-ribose on non-enzymatic glycation of hemoglobin (Hb), as well as eryptosis, oxidative stress and energy metabolism of erythrocytes were observed by molecular fluorescence spectrophotometry, multi-wavelength spectrophotometry, high-pressure liquid chromatography (HPLC), mass spectrometry (MS) and flow cytometer. The results showed that d-ribose had the strongest non-enzymatic glycation ability to Hb in vitro when compared with other monosaccharides, and could enter the erythrocytes in a concentration-dependent manner, which was not inhibited by the specific glucose transporter 1 (GLUT1) inhibitor WZB117. In addition, d-ribose incubation increased the HbA1c, hemolysis, eryptosis, and ROS level of erythrocytes significantly more than that of d-glucose, however, no changes were observed in the levels of ATP, NADPH, and other intermediate energy metabolites in d-ribose treatment. Therefore, the strong non-enzymatic glycation ability of d-ribose may play an important role in erythrocyte damage.
Collapse
Affiliation(s)
- Zehong Zhang
- Institute of Blood Conservation, Baotou Medical College, 31# Jianshe Road, Donghe District, 014040 Baotou, Inner Mongolia, China
| | - Yu Tai
- Institute of Blood Conservation, Baotou Medical College, 31# Jianshe Road, Donghe District, 014040 Baotou, Inner Mongolia, China
| | - Zhi Liu
- Institute of Blood Conservation, Baotou Medical College, 31# Jianshe Road, Donghe District, 014040 Baotou, Inner Mongolia, China
| | - Yunxia Pu
- Physical and Chemical Laboratory, Inner Mongolia Center for Disease Control and Prevention, South Section of Yongping Road, Xincheng District, 010080 Hohhot, Inner Mongolia, China
| | - Liang An
- Clinical Laboratory, The Fourth Hospital of Baotou, 1(#) Aogen Road, Qingshan District, 014030, Baotou, Inner Mongolia, China
| | - Xiaojing Li
- Institute of Blood Conservation, Baotou Medical College, 31# Jianshe Road, Donghe District, 014040 Baotou, Inner Mongolia, China
| | - Lili Li
- Institute of Blood Conservation, Baotou Medical College, 31# Jianshe Road, Donghe District, 014040 Baotou, Inner Mongolia, China
| | - Yaqi Wang
- Institute of Blood Conservation, Baotou Medical College, 31# Jianshe Road, Donghe District, 014040 Baotou, Inner Mongolia, China
| | - Zhongbin Yang
- Institute of Blood Conservation, Baotou Medical College, 31# Jianshe Road, Donghe District, 014040 Baotou, Inner Mongolia, China
| | - Chao Duan
- Institute of Blood Conservation, Baotou Medical College, 31# Jianshe Road, Donghe District, 014040 Baotou, Inner Mongolia, China
| | - Kun Hou
- Physical and Chemical Laboratory, Inner Mongolia Center for Disease Control and Prevention, South Section of Yongping Road, Xincheng District, 010080 Hohhot, Inner Mongolia, China
| | - Qing Zhang
- Physical and Chemical Laboratory, Inner Mongolia Center for Disease Control and Prevention, South Section of Yongping Road, Xincheng District, 010080 Hohhot, Inner Mongolia, China
| | - Fuyu Ren
- Institute of Blood Conservation, Baotou Medical College, 31# Jianshe Road, Donghe District, 014040 Baotou, Inner Mongolia, China
| | - Qiang Ma
- Institute of Blood Conservation, Baotou Medical College, 31# Jianshe Road, Donghe District, 014040 Baotou, Inner Mongolia, China.
| | - Yan Su
- Institute of Blood Conservation, Baotou Medical College, 31# Jianshe Road, Donghe District, 014040 Baotou, Inner Mongolia, China.
| |
Collapse
|
2
|
Wang Y, Shi C, Chen Y, Yu L, Li Y, Wei Y, Li W, He R. Formaldehyde produced from d-ribose under neutral and alkaline conditions. Toxicol Rep 2019; 6:298-304. [PMID: 31008059 PMCID: PMC6454226 DOI: 10.1016/j.toxrep.2019.02.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 02/18/2019] [Accepted: 02/24/2019] [Indexed: 12/09/2022] Open
Abstract
Formaldehyde is toxic and has been implicated in the pathologies of various diseases, such as cognitive impairment and cancer. Though d-ribose is widely studied and provided as a supplement to food such as flavor and drinks, no laboratories have reported that d-ribose is involved in the formaldehyde production. Here, we show that formaldehyde is produced from d-ribose in lysine or glycine solution and Tris-HCl buffer under neutral and alkaline conditions. Intraperitoneal injection of C57BL/6J mice with d-ribose significantly increased the concentration of brain formaldehyde, compared to the injection with d-glucose or saline. These data suggest that formaldehyde levels should be monitored for the people who take d-ribose as a supplement.
Collapse
Affiliation(s)
- Yujing Wang
- State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, University of Chinese Academy of Sciences, Beijing, 100101, China
| | - Chenggang Shi
- State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, University of Chinese Academy of Sciences, Beijing, 100101, China
| | - Yao Chen
- School of Basic Medical Sciences of Southwest Medical University, Luzhou, 646000, Sichuan, China
| | - Lexiang Yu
- State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, University of Chinese Academy of Sciences, Beijing, 100101, China
| | - Yiman Li
- The Department of Biomedical Sciences in Imperial College London, UK
| | - Yan Wei
- State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, University of Chinese Academy of Sciences, Beijing, 100101, China
| | - Weiwei Li
- Integrated Laboratory of TCM and Western Medicine, Peking University First Hospital, Xicheng District, Beijing, 100034, China
| | - Rongqiao He
- State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, University of Chinese Academy of Sciences, Beijing, 100101, China
| |
Collapse
|
3
|
Shecterle LM, Terry KR, St Cyr JA. Potential Clinical Benefits of D-ribose in Ischemic Cardiovascular Disease. Cureus 2018; 10:e2291. [PMID: 29750132 PMCID: PMC5943027 DOI: 10.7759/cureus.2291] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Cardiovascular disease still remains the leading cause of deaths worldwide. Atherosclerosis, the most common type of cardiovascular disease, has continued to progress due to many factors, genetics, and lifestyles. All cells require adequate adenosine triphosphate (ATP) levels to maintain their integrity and function. Myocardial ischemia commonly found in atherosclerosis can produce lower levels of ATP, which affects not only cellular energy, but also alters normal function. D-ribose, a naturally occurring pentose carbohydrate, has been shown to increase cellular energy levels and improve function following ischemia in pre-clinical studies and have demonstrated potential benefits in clinical evaluations. This review paper presents an overview of ischemic cardiovascular disease and the potential role that D-ribose could play in improving myocardial energy levels and function in the area of ischemic cardiovascular diseases.
Collapse
|
4
|
Houston M. The role of noninvasive cardiovascular testing, applied clinical nutrition and nutritional supplements in the prevention and treatment of coronary heart disease. Ther Adv Cardiovasc Dis 2018; 12:85-108. [PMID: 29316855 PMCID: PMC5933539 DOI: 10.1177/1753944717743920] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Accepted: 11/01/2017] [Indexed: 12/14/2022] Open
Abstract
Numerous clinical trials suggest that we have reached a limit in our ability to decrease the incidence of coronary heart disease (CHD) and cardiovascular disease (CVD) utilizing the traditional diagnostic evaluation, prevention and treatment strategies for the top five cardiovascular risk factors of hypertension, diabetes mellitus, dyslipidemia, obesity and smoking. About 80% of heart disease (heart attacks, angina, coronary heart disease and congestive heart failure) can be prevented by optimal nutrition, optimal exercise, optimal weight and body composition, mild alcohol intake and avoiding smoking. Statistics show that approximately 50% of patients continue to have CHD or myocardial infarction (MI) despite presently defined 'normal' levels of the five risk factors listed above. This is often referred to as the 'CHD gap'. Novel and more accurate definitions and evaluations of these top five risk factors are required, such as 24 h ambulatory blood pressure (ABM) results, advanced lipid profiles, redefined fasting and 2 h dysglycemia parameters, a focus on visceral obesity and body composition and the effects of adipokines on cardiovascular risk. There are numerous traumatic insults from the environment that damage the cardiovascular system but there are only three finite vascular endothelial responses, which are inflammation, oxidative stress and immune vascular dysfunction. In addition, the concept of translational cardiovascular medicine is mandatory in order to correlate the myriad of CHD risk factors to the presence or absence of functional or structural damage to the vascular system, preclinical and clinical CHD. This can be accomplished by utilizing advanced and updated CV risk scoring systems, new and redefined CV risk factors and biomarkers, micronutrient testing, cardiovascular genetics, nutrigenomics, metabolomics, genetic expression testing and noninvasive cardiovascular testing.
Collapse
Affiliation(s)
- Mark Houston
- Vanderbilt University Medical School, Hypertension Institute and Vascular Biology, Division of Human Nutrition, Saint Thomas Medical Group, Saint Thomas Hospital, 4230 Harding Rd, Suite 400, Nashville, TN 37205, USA
| |
Collapse
|
6
|
Jungnickel H, Luch A. A personalized life: biomarker monitoring from cradle to grave. EXPERIENTIA SUPPLEMENTUM (2012) 2012; 101:471-98. [PMID: 22945580 DOI: 10.1007/978-3-7643-8340-4_17] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Considering the holy grail of future medical treatment being personalized medicines, biomarker research will become more and more the focus for attention not only to develop new medical treatment regimes, based on changes in biomarker patterns, but also for nutritional advice to guarantee a lifelong optimized health condition. The current review gives an outline of how personalized medicine can become established for actual medical treatment using new biomarker concepts. Starting from the development of biomarker research using mainly immunological techniques, the review gives an overview about biomarkers of prediction evolved and focuses on new methodology for the identification of biomarkers using hyphenated analytical techniques like metabolomics and lipidomics. The actual use of multivariate statistical methods in combination with metabolomics and lipidomics is discussed not only for medical treatment but also for precautionary risk identification in human biomonitoring studies.
Collapse
Affiliation(s)
- Harald Jungnickel
- Department of Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589, Berlin, Gemany,
| | | |
Collapse
|